EU Authorized Representative for Singapore: Reliance Runs Only One Way

Reliance is a one-way street out of Singapore

HSA sorts product registration for Class B, C and D devices into route families that turn on one question: has an overseas reference regulatory agency already approved this device? The full route is for devices with, in HSA’s words, no prior approval by any of its overseas reference regulatory agencies. The abridged route needs approval from at least one of them. The expedited and immediate routes need one or two, plus clean marketing history. HSA names five: the Australian TGA, EU Notified Bodies, Health Canada, Japan’s MHLW and the US FDA.

So a European conformity assessment has explicit, written value in Singapore. Regulatory teams here grow up with the idea that approvals travel. Travelling the other way, they do not travel at all. The Regulation says only this: "Prior to placing a device on the market, manufacturers shall undertake an assessment of the conformity of that device, in accordance with the applicable conformity assessment procedures set out in Annexes IX to XI." (MDR Art. 52(1)) There is no abridged Annex, no reference-agency shortcut, and no discretion for a notified body to shorten a file because HSA already looked at it.

The reference agency you cannot invoke in reverse

The asymmetry is structural rather than political. HSA is a national authority that can decide, as a matter of its own procedure, how much weight to give a foreign decision. In the Union the assessment is not made by an authority at all: it is made by a notified body designated under MDR Article 42 and monitored against Annex VII, working to conformity assessment procedures fixed in the Regulation itself. A notified body has no lawful mechanism for recognising an SMDR entry, and would be sanctioned by its designating authority for trying.

The practical consequence for a Singapore exporter is that the sequencing most companies expect is inverted. Rather than Singapore first and Europe second on the strength of it, most portfolios are better served by building the European file to Annex II standard and then feeding the resulting notified body certificate back into an abridged HSA submission for the next product generation.

A CSDT dossier is a good start and a poor finish

Singapore submissions are built on the ASEAN Common Submission Dossier Template, and HSA publishes dedicated guidance on preparing CSDT submissions for both general medical devices and IVDs. The CSDT is a genuine asset. Its device description, design verification and validation, labelling, risk analysis and manufacturer information sections all have recognisable counterparts in MDR Annex II.

What it does not contain is the part that consumes the schedule:

• a general safety and performance requirements checklist worked line by line against Annex I, naming the harmonised standard or common specification relied on and the exact document that demonstrates each point — the ASEAN Essential Principles conformity checklist is shorter and differently structured;
• a clinical evaluation conducted under Article 61 and documented per Annex XIV Part A, with a clinical evaluation plan and a defensible equivalence argument if literature is used;
• a post-market surveillance plan under Article 84 and Annex III, and for class IIa and above a periodic safety update report under Article 86;
• UDI assignment, including the Basic UDI-DI that keys the device into EUDAMED and onto the declaration of conformity.

Class B in the Register, class IIa in the Union

Singapore’s A-to-D classification derives from the ASEAN risk rules. MDR Annex VIII runs to twenty-two rules across four chapters, with its own definitions of transient, short-term and long-term use and its own treatment of software, substances and nanomaterials. The letters coincide in count and in nothing else, and Annex VIII Chapter II makes clear that where several rules apply, the strictest one governs. Reading a European class off a Singapore registration is the single most common way a project loses a quarter, because the conformity assessment route — and therefore the budget — is decided by that class.

Registrant, dealer, representative: three different jobs

Singapore roles do not map onto MDR economic operators, and assuming they do produces contracts that allocate obligations to parties who cannot lawfully hold them.

From English-only labelling to twenty-four languages

A Singapore file is written once, in English, and that is the end of the language question. In the Union each Member State determines the official language or languages in which the information accompanying the device must be supplied, and the obligation attaches to the manufacturer, not to the distributor who happens to be selling there. A launch across Germany, France, Poland and Spain is four regulated translations of the instructions for use and the label, each of which has to be controlled inside the quality management system and re-issued whenever the design changes. Companies used to a single-language home market routinely underestimate this by an order of magnitude.

Setting up the mandate from a Singapore head office

Under MDR Article 11(1) a manufacturer outside the Union may place a device on the Union market only through a single designated representative, and under Article 11(2) the designation is effective only when accepted in writing and covers at least all devices in the same generic device group. Among the tasks the mandate must confer is the duty to "comply with the registration obligations laid down in Article 31 and verify that the manufacturer has complied with the registration obligations laid down in Articles 27 and 29;" (MDR Art. 11(3)(c)) — which is why the representative appointment and the EUDAMED actor and device registration are one workstream, not two.

Medex acts under EUDAMED authorised representative SRN TR-AR-000057550, and is separately registered as a manufacturer, TR-MF-000057496, and as an importer. The person responsible for regulatory compliance is in-house, a partner of the firm, with a named deputy, so the Article 15 requirement is met by people who are answerable for it rather than by a subcontracted rota. Offices are in Ankara, İstanbul and Gdańsk. Fees are published and set by device class, from EUR 1000 a year. The scope of the mandate itself is set out on our EU Authorized Representative service page.

Questions from Singapore registrants and Tuas plants

We hold a Class C registration in the Singapore Medical Device Register. Does it shorten anything in Europe?

No. It shortens nothing and satisfies no requirement. The evidence underneath it — test reports, biocompatibility, sterilisation validation, clinical data — is reusable, and often most of it survives. The registration itself, the HSA review and the SMDR entry have no standing under MDR at all.

Our CSDT dossier was accepted by HSA. Will the notified body work from it?

It will accept the underlying reports, but not the dossier as submitted. Annex II prescribes a structure and a level of granularity the CSDT does not reach, and the GSPR checklist has to be rebuilt against Annex I rather than against the ASEAN Essential Principles. Budget for a restructuring exercise, not a re-format.

Can our Singapore registrant also act as our EU representative?

Only if it is a legal person established in a Member State, which a Singapore registrant is not. The representative under Article 11 must be established within the Union, must accept the mandate in writing, and under Article 11(5) becomes jointly and severally liable with the manufacturer for defective devices where the manufacturer has not met its Article 10 obligations. That is not a role a distributor takes on casually.

Do we need an EU importer as well?

Yes, if anyone is bringing your device from Singapore into the Union — that party is the importer under Article 13, has its own verification duties, must appear on the device or its packaging, and needs its own SRN. The representative does not absorb that role. If you have not yet decided who it will be, tell us the destination markets and we will map the operator chain before the first shipment.